Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
File(s)
Author(s)
Type
Journal Article
Abstract
Background
Statins are first-line therapy for cardiovascular disease prevention, but their systemic effects across lipoprotein subclasses, fatty acids, and circulating metabolites remain incompletely characterized.
Objectives
This study sought to determine the molecular effects of statin therapy on multiple metabolic pathways.
Methods
Metabolic profiles based on serum nuclear magnetic resonance metabolomics were quantified at 2 time points in 4 population-based cohorts from the United Kingdom and Finland (N = 5,590; 2.5 to 23.0 years of follow-up). Concentration changes in 80 lipid and metabolite measures during follow-up were compared between 716 individuals who started statin therapy and 4,874 persistent nonusers. To further understand the pharmacological effects of statins, we used Mendelian randomization to assess associations of a genetic variant known to mimic inhibition of HMG-CoA reductase (the intended drug target) with the same lipids and metabolites for 27,914 individuals from 8 population-based cohorts.
Results
Starting statin therapy was associated with numerous lipoprotein and fatty acid changes, including substantial lowering of remnant cholesterol (80% relative to low-density lipoprotein cholesterol [LDL-C]), but only modest lowering of triglycerides (25% relative to LDL-C). Among fatty acids, omega-6 levels decreased the most (68% relative to LDL-C); other fatty acids were only modestly affected. No robust changes were observed for circulating amino acids, ketones, or glycolysis-related metabolites. The intricate metabolic changes associated with statin use closely matched the association pattern with rs12916 in the HMGCR gene (R2 = 0.94, slope 1.00 ± 0.03).
Conclusions
Statin use leads to extensive lipid changes beyond LDL-C and appears efficacious for lowering remnant cholesterol. Metabolomic profiling, however, suggested minimal effects on amino acids. The results exemplify how detailed metabolic characterization of genetic proxies for drug targets can inform indications, pleiotropic effects, and pharmacological mechanisms.
Statins are first-line therapy for cardiovascular disease prevention, but their systemic effects across lipoprotein subclasses, fatty acids, and circulating metabolites remain incompletely characterized.
Objectives
This study sought to determine the molecular effects of statin therapy on multiple metabolic pathways.
Methods
Metabolic profiles based on serum nuclear magnetic resonance metabolomics were quantified at 2 time points in 4 population-based cohorts from the United Kingdom and Finland (N = 5,590; 2.5 to 23.0 years of follow-up). Concentration changes in 80 lipid and metabolite measures during follow-up were compared between 716 individuals who started statin therapy and 4,874 persistent nonusers. To further understand the pharmacological effects of statins, we used Mendelian randomization to assess associations of a genetic variant known to mimic inhibition of HMG-CoA reductase (the intended drug target) with the same lipids and metabolites for 27,914 individuals from 8 population-based cohorts.
Results
Starting statin therapy was associated with numerous lipoprotein and fatty acid changes, including substantial lowering of remnant cholesterol (80% relative to low-density lipoprotein cholesterol [LDL-C]), but only modest lowering of triglycerides (25% relative to LDL-C). Among fatty acids, omega-6 levels decreased the most (68% relative to LDL-C); other fatty acids were only modestly affected. No robust changes were observed for circulating amino acids, ketones, or glycolysis-related metabolites. The intricate metabolic changes associated with statin use closely matched the association pattern with rs12916 in the HMGCR gene (R2 = 0.94, slope 1.00 ± 0.03).
Conclusions
Statin use leads to extensive lipid changes beyond LDL-C and appears efficacious for lowering remnant cholesterol. Metabolomic profiling, however, suggested minimal effects on amino acids. The results exemplify how detailed metabolic characterization of genetic proxies for drug targets can inform indications, pleiotropic effects, and pharmacological mechanisms.
Date Issued
2016-03-07
Date Acceptance
2015-12-22
Citation
Journal of the American College of Cardiology, 2016, 67 (10), pp.1200-1210
ISSN
1558-3597
Publisher
Elsevier
Start Page
1200
End Page
1210
Journal / Book Title
Journal of the American College of Cardiology
Volume
67
Issue
10
Copyright Statement
© 2016 The Authors. This is an Open Access article under the CC BY-NC-ND License.
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
cholesterol lowering
drug development
lipoproteins
Mendelian randomization
metabolomics
GENOME-WIDE ASSOCIATION
CORONARY-HEART-DISEASE
FATTY-ACID-COMPOSITION
LDL CHOLESTEROL
MENDELIAN RANDOMIZATION
CARDIOVASCULAR-DISEASE
COHORT PROFILE
RISK
TRIGLYCERIDES
EPIDEMIOLOGY
Adult
Cardiovascular Diseases
Female
Finland
Forecasting
Great Britain
Humans
Hydroxymethylglutaryl CoA Reductases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Magnetic Resonance Spectroscopy
Male
Mendelian Randomization Analysis
Metabolomics
Middle Aged
Retrospective Studies
Cardiovascular System & Hematology
1102 Cardiovascular Medicine And Haematology
1117 Public Health And Health Services
Publication Status
Published